Fertilizante de liberação lenta no desenvolvimento de mudas de Eucalyptus grandis.

Uma das ações mais importantes para aumentar a produção de mudas de essências florestais é a fertilização do substrato. A utilização de fertilizante de liberação lenta (FLL) pode contribuir para a obtenção de mudas de melhor qualidade. O objetivo do trabalho foi avaliar doses crescentes de FLL e fertilizante convencional (FC), bem como comparar esses fertilizantes no desenvolvimento de mudas de Eucalyptus grandis. O estudo foi realizado na região do Vale do Itajaí, SC. Os tratamentos foram a adição de FLL e FC para cada experimento nas seguintes doses de formulado: T1 ? 0 kg (testemunha); T2 ? 2 kg; T3 ? 4 kg; T4 ? 6 kg; T5 ? 8 kg e T6 ? 10 kg.m-3 de substrato-base. Decorridos 174 dias da semeadura, foram analisadas as variáveis altura total, diâmetro do colo, biomassa fresca da parte aérea, biomassa seca da parte aérea, biomassa seca da raiz, biomassa seca total, dose de máxima eficiência técnica e teores de nutrientes da parte aérea das mudas de cada tratamento. Em todos os tratamentos houve resposta positiva no desenvolvimento das mudas, entretanto as mudas tiveram melhor crescimento sob doses entre 9,1 e 12,9 kg.m-3 de fertilizante de liberação lenta

o 002geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma mpac patients in real world across europe

n/

p 167symptoms reported at initial diagnosis of metastatic pancreatic adenocarcinoma m pac in routine clinical practice and variation in frequencies across europe

n/

pd 004baseline characteristics and second line treatment for metastatic pancreatic adenocarcinoma mpac patients receiving first line folfirinox gemcitabine nab paclitaxel or gemcitabine monotherapy in routine clinical practice across europe

n/

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

Abstract Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence of NTRK gene fusions. NTRK fusion-positive tumours were identified from the FoundationCORE® database of >295,000 cancer patients. We investigated the prevalence and concomitant genomic landscape of NTRK fusions, predicted patient ancestry and compared the FoundationCORE cohort with entrectinib clinical trial cohorts (ALKA-372-001 [EudraCT 2012-000148-88]; STARTRK-1 [NCT02097810]; STARTRK-2 [NCT02568267]). Overall NTRK fusion-positive tumour prevalence was 0.30% among 45 cancers with 88 unique fusion partner pairs, of which 66% were previously unreported. Across all cases, prevalence was 0.28% and 1.34% in patients aged ≥18 and <18 years, respectively; prevalence was highest in patients <5 years (2.28%). The highest prevalence of NTRK fusions was observed in salivary gland tumours (2.62%). Presence of NTRK gene fusions did not correlate with other clinically actionable biomarkers; there was no co-occurrence with known oncogenic drivers in breast, or colorectal cancer (CRC). However, in CRC, NTRK fusion-positivity was associated with spontaneous microsatellite instability (MSI); in this MSI CRC subset, mutual exclusivity with BRAF mutations was observed. NTRK fusion-positive tumour types had similar frequencies in FoundationCORE and entrectinib clinical trials. NTRK gene fusion prevalence varied greatly by age, cancer type and histology. Interrogating large datasets drives better understanding of the characteristics of very rare molecular subgroups of cancer and allows identification of genomic patterns and previously unreported fusion partners not evident in smaller datasets

Avaliação da produção de matéria seca radicular de diferentes coberturas de solo, no período de inverno nas entrelinhas de erva-mate no município de Aurea, RS.

bitstream/CNPF-2009-09/16600/1/com_tec27.pd

Produtividade de massas radicular e aérea de diferentes coberturas verdes em plantio de erva-mate sobre cambissolo textura argilosa, no Município de Ivaí-PR.

bitstream/CNPF-2009-09/32742/1/com_tec79.pd

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease

Background: In certain malignancies, patients with oligometastatic disease benefit from radical ablative or surgical treatment. The SABR-COMET trial demonstrated a survival benefit for oligometastatic patients randomized to local stereotactic ablative radiation (SABR) compared to patients receiving standard care (SC) alone. Our aim was to determine the cost-effectiveness of SABR. Materials and Methods: A decision model based on partitioned survival simulations estimated costs and quality-adjusted life years (QALY) associated with both strategies in a United States setting from a health care perspective. Analyses were performed over the trial duration of six years as well as a long-term horizon of 16 years. Model input parameters were based on the SABR-COMET trial data as well as best available and most recent data provided in the published literature. An annual discount of 3% for costs was implemented in the analysis. All costs were adjusted to 2019 US Dollars according to the United States Consumer Price Index. SABR costs were reported with an average of $11,700 per treatment. Deterministic and probabilistic sensitivity analyses were performed. Incremental costs, effectiveness, and cost-effectiveness ratios (ICER) were calculated. The willingness-to-pay (WTP) threshold was set to$100,000/QALY. Results: Based on increased overall and progression-free survival, the SABR group showed 0.78 incremental QALYs over the trial duration and 1.34 incremental QALYs over the long-term analysis. Treatment with SABR led to a marginal increase in costs compared to SC alone (SABR: $304,656; SC:$303,523 for 6 years; ICER $1,446/QALY and SABR:$402,888; SC: $350,708 for long-term analysis; ICER$38,874/QALY). Therapy with SABR remained cost-effective until treatment costs of $88,969 over the trial duration (i.e. 7.6 times the average cost). Sensitivity analysis identified a strong model impact for ongoing annual costs of oligo- and polymetastatic disease states. Conclusion: Our analysis suggests that local treatment with SABR adds QALYs for patients with certain oligometastatic cancers and represents an intermediate- and long-term cost-effective treatment strategy

Desenvolvimento de leguminosas arbóreas em sistema de alley cropping, em solos degradados pela mineração de xisto pirobetuminoso, em São Mateus do Sul, PR.

bitstream/CNPF-2009-09/16607/1/com_tec28.pd

Caracterização de sementes de cornichão (Lotus corniculatus L.) e desenvolvimento de suspensões para recobrimento.

Objetivo desse trabalho foi caracterizar física e fisiologicamente as sementes de cornichão a fim de conhecer suas propriedades e elaborar filmes para seu recobrimento que apresentem potencial protetor, melhorem as características físicas e que apresentem as características necessárias para atomização em futuros trabalhos de recobrimento em leito de jorro.ENEMP